drugset / Trial / NCT06900192

A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis

NCT06900192

Phase 1 Not yet recruiting 10 enrolled Stanford University Orca Biosystems, Inc. · collab
NaSequentialOpen-labelTreatment

Summary

A study of alloHCT with Orca-Q for the treatment of primary progressive multiple sclerosis (MS).

Timeline

Start
2025-03
Primary completion
2029-08
Completion
2029-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Orca-Q Cell therapy
Background Busulfan Small molecule
Background Fludarabine Small molecule
Background Thiotepa Other / unclassified